{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:58Z","timestamp":1792786138517,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"name":"National Institute of General Medical Sciences","award":["R35GM146701"],"award-info":[{"award-number":["R35GM146701"]}],"id":[{"id":"https:\/\/ror.org\/04q48ey07","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study describes the first-year experience with a model-informed precision dosing (MIPD) consultation service for cefepime at a quaternary children's hospital, including patient characteristics, turnaround times, process barriers, and the impact of dosing recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This prospective observational study included data from all cefepime MIPD consultations from August 2024 to August 2025. Demographic, clinical, microbiologic, and treatment data were obtained from electronic health records. Timeliness was evaluated by tracking timestamps from consult order to result communication and dose adjustment. The analysis examined whether recommendations led to changes in dose, dosing frequency, or infusion duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Nineteen patients (median age 2.7 years, range 1 month\u201327.7 years) received a total of 20 cefepime MIPD consultations. Infection sources included bloodstream, abdomen, respiratory tract, central nervous system, peritoneal dialysis catheter, and urine. Half of the patients required extracorporeal support. Organisms were isolated in 10 patients (cefepime MICs &lt;0.12\u20138 mg\/L), whereas others were dosed empirically. Recommendations were provided a median of 27.8 hours after consultation order (range 6.6\u201382.4 hours). Eight (40%) recommendations supported continuing the existing regimen, and 10 (50%) resulted in new dosing strategies. In 1 case (5%), cefepime was changed to meropenem owing to concern about possible neurotoxicity, and in another, the family opted for comfort-focused care before recommendations could be provided. Challenges included logistical barriers, communication gaps, insufficient training, system limitations, and clinical issues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These findings support the feasibility and clinical utility of an MIPD consultation service for cefepime. The service enabled timely identification of high or low exposures, including in patients on extracorporeal support, and guided individualized dosing decisions to optimize target attainment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001520","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:00:10Z","timestamp":1789682410000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Implementing a Model-Informed Precision Dosing Service for Cefepime in a Quaternary Children's Hospital: A First-Year Experience"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5856-3717","authenticated-orcid":false,"given":"Ronaldo","family":"Morales Junior","sequence":"first","affiliation":[{"name":"Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Diseroad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Reinert","sequence":"additional","affiliation":[{"name":"Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;"},{"name":"Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio;"},{"name":"Division of Critical Care Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poongothai","family":"Venkatachalapathy","sequence":"additional","affiliation":[{"name":"Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Rhodes","family":"Hambrick","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois;"},{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Tang Girdwood","sequence":"additional","affiliation":[{"name":"Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio;"},{"name":"Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; and"},{"name":"Division of Hospital Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"R1-20260917","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-022-01137-y","article-title":"Clinical pharmacokinetics and pharmacodynamics of cefepime","volume":"61","author":"Pais","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R2-20260917","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40262-025-01485-5","article-title":"Population pharmacokinetics of cefepime in critically ill children and young adults: model development and external validation for monte carlo simulations and model-informed precision dosing","volume":"64","author":"Morales Junior","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jcph.1773","article-title":"Demonstrating feasibility of an opportunistic sampling approach for pharmacokinetic studies of \u03b2-lactam antibiotics in critically ill children","volume":"61","author":"Tang Girdwood","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijantimicag.2013.11.006","article-title":"Dose optimisation of antibiotics in children: application of pharmacokinetics\/pharmacodynamics in paediatrics","volume":"43","author":"Downes","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R5-20260917","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/bcp.70120","article-title":"Unveiling predisposing factors for cefepime-induced neurotoxicity: a systematic review and meta-analysis","volume":"91","author":"Hardi","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"e70438","DOI":"10.1111\/cts.70438","article-title":"Building a beta-lactam model-informed precision dosing service in a quaternary care children's hospital","volume":"18","author":"Tang Girdwood","year":"2025","journal-title":"Clin Transl Sci"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1128\/AAC.02592-15","article-title":"Population pharmacokinetic assessment and pharmacodynamic implications of pediatric cefepime dosing for susceptible-dose-dependent organisms","volume":"60","author":"Shoji","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-20260917","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40560-024-00752-0","article-title":"Monte Carlo simulations of cefepime in children receiving continuous kidney replacement therapy support continuous infusions for target attainment","volume":"12","author":"Hambrick","year":"2024","journal-title":"J Intensive Care"},{"key":"R11-20260917","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00134-014-3391-8","article-title":"Validation of the KDIGO acute kidney injury criteria in a pediatric critical care population","volume":"40","author":"Selewski","year":"2014","journal-title":"Intensive Care Med"},{"key":"R12-20260917","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/sdi.12496","article-title":"We underdose antibiotics in patients on CRRT","volume":"29","author":"Shaw","year":"2016","journal-title":"Semin Dial"},{"key":"R13-20260917","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jac5.1819","article-title":"How to\u2019 guide for pharmacist-led implementation of beta-lactam therapeutic drug monitoring in the critically ill","volume":"6","author":"Ausman","year":"2023","journal-title":"J Am Coll Clin Pharm"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"100011","DOI":"10.1016\/j.cmicom.2024.100011","article-title":"Cefepime trough levels and clinical outcomes in patients undergoing universal therapeutic drug monitoring: a prospective cohort study","volume":"1","author":"Lid\u00e9n","year":"2024","journal-title":"CMI Commun"},{"key":"R15-20260917","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/ajhp\/zxac171","article-title":"Implementation of a \u03b2-lactam therapeutic drug monitoring program: experience from a large academic medical center","volume":"79","author":"Venugopalan","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"dlac043","DOI":"10.1093\/jacamr\/dlac043","article-title":"Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing","volume":"4","author":"Suttels","year":"2022","journal-title":"JAC-Antimicrob Resist"},{"key":"R17-20260917","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/phar.2744","article-title":"Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity","volume":"43","author":"Venugopalan","year":"2023","journal-title":"Pharmacotherapy"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R19-20260917","doi-asserted-by":"crossref","first-page":"107809","DOI":"10.1016\/j.ijantimicag.2026.107809","article-title":"Model-informed cefepime dosing in paediatric patients receiving continuous renal replacement therapy","volume":"67","author":"Morales Junior","year":"2026","journal-title":"Int J Antimicrob Agents"},{"key":"R20-20260917","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A guide to therapeutic drug monitoring of \u03b2-lactam antibiotics","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy"},{"key":"R21-20260917","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/CCM.0000000000002817","article-title":"\u03b2-lactam therapeutic drug management in the PICU","volume":"46","author":"Cies","year":"2018","journal-title":"Crit Care Med"},{"key":"R22-20260917","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/08971900221125000","article-title":"Cefepime-associated neurotoxicity in a pediatric patient with stage V chronic kidney disease","volume":"37","author":"Hambrick","year":"2024","journal-title":"J Pharm Pract"},{"key":"R23-20260917","doi-asserted-by":"crossref","first-page":"dkag075","DOI":"10.1093\/jac\/dkag075","article-title":"Identification and assessment of paediatric cefepime-induced neurotoxicity in a retrospective cohort of paediatric intensive care patients","volume":"81","author":"Pavia","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"R24-20260917","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/PCC.0000000000003927","article-title":"Surviving sepsis campaign international guidelines for the management of sepsis and septic shock in children 2026","volume":"27","author":"Weiss","year":"2026","journal-title":"Pediatr Crit Care Med"},{"key":"R25-20260917","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00134-026-08361-1","article-title":"Surviving sepsis Campaign: international guidelines for management of sepsis and septic shock 2026","volume":"52","author":"Prescott","year":"2026","journal-title":"Intensive Care Med"},{"key":"R26-20260917","doi-asserted-by":"crossref","first-page":"124996","DOI":"10.1016\/j.talanta.2023.124996","article-title":"Overview of therapeutic drug monitoring and clinical practice","volume":"266","author":"Fang","year":"2024","journal-title":"Talanta"},{"key":"R27-20260917","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/FTD.0000000000001059","article-title":"Why is the implementation of beta-lactam therapeutic drug monitoring for the critically ill falling short? A multicenter mixed-methods study","volume":"45","author":"Barreto","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R28-20260917","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/CCM.0000000000002012","article-title":"Chronic kidney disease after acute kidney injury requiring continuous renal replacement therapy and its impact on long-term outcomes: a multicenter retrospective cohort study in Korea","volume":"45","author":"An","year":"2017","journal-title":"Crit Care Med"},{"key":"R29-20260917","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s10157-018-1595-x","article-title":"Long-term outcomes in acute kidney injury patients who underwent continuous renal replacement therapy: a single-center experience","volume":"22","author":"Rhee","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"R30-20260917","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"key":"R31-20260917","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s00134-022-06921-9","article-title":"Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial","volume":"48","author":"Ewoldt","year":"2022","journal-title":"Intensive Care Med"},{"key":"R32-20260917","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-Lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"R33-20260917","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/FTD.0000000000000937","article-title":"Barriers and facilitators in the clinical implementation of beta-lactam therapeutic drug monitoring in critically ill patients: a critical review","volume":"44","author":"Abdulla","year":"2022","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:00:15Z","timestamp":1789682415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001520","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"2026-04-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}